Leerink initiated coverage of Inventiva (IVA) with an Outperform rating and $12 price target The company is a is clinical-stage biotech advancing lanifibranor, a once- daily oral pan-PPAR agonist, for the treatment of metabolic dysfunction-associated steatohepatitis, the analyst tells investors in a research note. The firm says lanifibranor’s balanced activation of all three PPAR isoforms positions it to directly address the core drivers of MASH.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- Inventiva upgraded to Buy from Neutral at UBS
- Aligos Therapeutics initiated with a Buy at UBS
- Inventiva’s Shareholders’ Meeting Results in Key Resolutions Approval
- Positive Buy Rating for Inventiva Driven by Promising Phase 3 Trial and Strong Financial Position
- Inventiva price target lowered to $11 from $13 at Guggenheim